These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 12916922)

  • 1. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug.
    Sethuraman VV; Hickey AJ
    AAPS PharmSciTech; 2002; 3(4):E28. PubMed ID: 12916922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin.
    Hamishehkar H; Emami J; Najafabadi AR; Gilani K; Minaiyan M; Mahdavi H; Nokhodchi A
    Int J Pharm; 2010 Apr; 389(1-2):74-85. PubMed ID: 20085803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
    Pai RV; Jain RR; Bannalikar AS; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifapentine-loaded PLGA microparticles for tuberculosis inhaled therapy: Preparation and in vitro aerosol characterization.
    Parumasivam T; Leung SS; Quan DH; Triccas JA; Britton WJ; Chan HK
    Eur J Pharm Sci; 2016 Jun; 88():1-11. PubMed ID: 27049049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Granulated Lactose as a Carrier for Dry Powder Inhaler Formulations 2: Effect of Drugs and Drug Loading.
    Du P; Du J; Smyth HDC
    J Pharm Sci; 2017 Jan; 106(1):366-376. PubMed ID: 27939234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. Albuterol sulfate and disodium cromoglycate.
    Xu Z; Mansour HM; Mulder T; McLean R; Langridge J; Hickey AJ
    J Pharm Sci; 2010 Aug; 99(8):3398-414. PubMed ID: 20198688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of sustained release rifampicin microparticles for inhalation.
    Son YJ; McConville JT
    J Pharm Pharmacol; 2012 Sep; 64(9):1291-302. PubMed ID: 22881441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of lactose carrier on the powder behavior and aerodynamic performance of bosentan microparticles for dry powder inhalation.
    Lee HJ; Lee HG; Kwon YB; Kim JY; Rhee YS; Chon J; Park ES; Kim DW; Park CW
    Eur J Pharm Sci; 2018 May; 117():279-289. PubMed ID: 29510172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
    Rawal T; Kremer L; Halloum I; Butani S
    J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and evaluation of poly(lactic-co-glycolic acid) microparticles as a carrier for pulmonary delivery of recombinant human interleukin-2: II. In vitro studies on aerodynamic properties of dry powder inhaler formulations.
    Devrim B; Bozkır A; Canefe K
    Drug Dev Ind Pharm; 2011 Nov; 37(11):1376-86. PubMed ID: 21548727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis.
    Ohashi K; Kabasawa T; Ozeki T; Okada H
    J Control Release; 2009 Apr; 135(1):19-24. PubMed ID: 19121349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneously manufactured nano-in-micro (SIMANIM) particles for dry-powder modified-release delivery of antibodies.
    Kaye RS; Purewal TS; Alpar HO
    J Pharm Sci; 2009 Nov; 98(11):4055-68. PubMed ID: 19189420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of rifampicin-loaded PLGA microspheres for lung delivery as aerosol by premix membrane homogenization.
    Doan TV; Olivier JC
    Int J Pharm; 2009 Dec; 382(1-2):61-6. PubMed ID: 19682562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN; Bierend H; Robins E; Steckel H; Flament MP
    Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
    Schiavone H; Palakodaty S; Clark A; York P; Tzannis ST
    Int J Pharm; 2004 Aug; 281(1-2):55-66. PubMed ID: 15288343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model.
    Suarez S; O'Hara P; Kazantseva M; Newcomer CE; Hopfer R; McMurray DN; Hickey AJ
    Pharm Res; 2001 Sep; 18(9):1315-9. PubMed ID: 11683246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.